Docoh
Loading...

RGLS Regulus Therapeutics

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”) was held on June 14, 2021. As of April 16, 2021, the record date for the 2021 Annual Meeting, 74,923,660 shares of common stock were issued and outstanding. A summary of the matters voted upon at the 2021 Annual Meeting and the final voting results are set forth below.

Proposal 1. Election of Directors

The ten persons listed below were elected as directors at the 2021 Annual Meeting, each to serve until the Company’s 2022 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results were as follows:

Votes ForVotes WithheldBroker Non-Votes
David Baltimore, Ph.D.33,261,900476,47322,067,104
Kathryn J. Collier33,134,897603,47622,067,104
Joseph P. Hagan33,071,791666,85222,067,104
Alice S. Huang, Ph.D.33,173,884564,48922,067,104
Jake R. Nunn32,974,690763,68322,067,104
Stelios Papadopoulos, Ph.D.33,247,920490,45322,067,104
William Rastetter, Ph.D.33,062,513675,86022,067,104
Hugh Rosen, M.D., Ph.D.33,123,204615,16922,067,104
Simos Simeonidis, Ph.D.33,182,719555,65422,067,104
Pascale Witz, MBA, MSc33,053,460684,91322,067,104


Proposal 2. The Company’s stockholders approved the Charter Amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. The final voting results were as follows:

Votes ForVotes AgainstAbstentions
50,555,9595,148,013101,505


Proposal 3. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the 2021 Annual Meeting. The final voting results were as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes
32,643,5801,013,00081,79322,067,104


Proposal 4. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results were as follows:

Votes ForVotes AgainstAbstentions
54,939,010494,268372,199


Proposal 5. The Company’s stockholders approved the authorization to adjourn the 2021 Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 2. The final voting results were as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes
32,592,7351,048,82496,81422,067,104